Equity research - Bayer ag: the growth path for a pharma titan
One of Bayer AG’s strongest assets and operational flagship across the globe has been its pharmaceutical division, which comprisesroughly40% of total sales of the group, as of 2020. However, it is now dealing with major business shifts which undermine its the medium-term growth prospects, as its two...
| Autor principal: | |
|---|---|
| Formato: | masterThesis |
| Idioma: | eng |
| Publicado em: |
2022
|
| Assuntos: | |
| Texto completo: | http://hdl.handle.net/10362/140596 |
| País: | Portugal |
| Oai: | oai:run.unl.pt:10362/140596 |